Literature DB >> 16637825

Brief report: physicians and their personal prostate cancer-screening practices with prostate-specific antigen. A national survey.

Evelyn C Y Chan1, Michael J Barry, Sally W Vernon, Chul Ahn.   

Abstract

BACKGROUND: There is inconclusive evidence that prostate cancer screening with prostate-specific antigen (PSA) reduces mortality. Although PSA testing is widespread, it is unknown how many physicians have taken the PSA test themselves.
OBJECTIVE: To determine the prevalence of PSA testing among physicians.
DESIGN: Cross-sectional survey.
SUBJECTS: A nationwide stratified random sample of urologists (response rate 61%, n=247), Internists (response rate 51%, n=273), and family physicians (response rate 64%, n=249) were surveyed by mail in 2000. After excluding female respondents and men who either reported a positive history of prostate cancer or did not respond to that query, there were 146 urologists, 96 Internists, and 118 family physicians. MEASUREMENTS: Whether physicians had undergone prostate cancer screening with PSA.
RESULTS: Eighty-seven percent (155/178) of male physicians aged, 50 and older and 21% (31/150) of white male physicians under age 50 reported having had a PSA test. More urologists than nonurologists in both age groups reported having had a screening PSA test.
CONCLUSION: Most physicians aged 50 and older report undergoing PSA testing. This may reflect a belief in its efficacy and contribute to its widespread use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16637825      PMCID: PMC1828086          DOI: 10.1111/j.1525-1497.2006.00327.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  18 in total

1.  Screening for prostate cancer: recommendation and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-12-03       Impact factor: 25.391

2.  Prostate cancer screening practices and beliefs.

Authors:  J D Voss; J M Schectman
Journal:  J Gen Intern Med       Date:  2001-12       Impact factor: 5.128

3.  Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA).

Authors: 
Journal:  Oncology (Williston Park)       Date:  2000-02       Impact factor: 2.990

4.  Knowledge, attitudes and experience associated with testing for prostate cancer: a comparison between male doctors and men in the community.

Authors:  P Livingston; P Cohen; M Frydenberg; R Borland; D Reading; V Clarke; D Hill
Journal:  Intern Med J       Date:  2002 May-Jun       Impact factor: 2.048

5.  Psychological benefits of prostate cancer screening: the role of reassurance.

Authors:  Scott B Cantor; Robert J Volk; Alvah R Cass; Jawaria Gilani; Stephen J Spann
Journal:  Health Expect       Date:  2002-06       Impact factor: 3.377

6.  The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam.

Authors:  F H Schröder; R Kranse; J Rietbergen; R Hoedemaeke; W Kirkels
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

7.  Family history and the risk of prostate cancer.

Authors:  L A Kalish; W S McDougal; J B McKinlay
Journal:  Urology       Date:  2000-11-01       Impact factor: 2.649

8.  Prostate-specific antigen test use reported in the 2000 National Health Interview Survey.

Authors:  Louie E Ross; Ralph J Coates; Nancy Breen; Robert J Uhler; Arnold L Potosky; Donald Blackman
Journal:  Prev Med       Date:  2004-06       Impact factor: 4.018

9.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

Authors:  Brenda E Sirovich; Lisa M Schwartz; Steven Woloshin
Journal:  JAMA       Date:  2003-03-19       Impact factor: 56.272

10.  Physician perspectives on the importance of facts men ought to know about prostate-specific antigen testing.

Authors:  Evelyn C Y Chan; Sally W Vernon; Michelle C Haynes; Frederick T O'Donnell; Chul Ahn
Journal:  J Gen Intern Med       Date:  2003-05       Impact factor: 5.128

View more
  7 in total

1.  Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.

Authors:  Michael W Drazer; Dezheng Huo; Mara A Schonberg; Aria Razmaria; Scott E Eggener
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

2.  Exploring patient perceptions of PSA screening for prostate cancer: risks, effectiveness, and importance.

Authors:  Scott D Smith; Richard Birtwhistle
Journal:  Can Fam Physician       Date:  2012-09       Impact factor: 3.275

3.  Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

Authors:  Stacy Loeb; E Jeffrey Metter; Donghui Kan; Kimberly A Roehl; William J Catalona
Journal:  BJU Int       Date:  2012-02-01       Impact factor: 5.588

4.  Prostate cancer screening trends in a large, integrated health care system.

Authors:  Lauren Wallner; Stanley Frencher; Jin-Wen Hsu; Ronald Loo; Joice Huang; Michael Nichol; Steven Jacobsen
Journal:  Perm J       Date:  2012

5.  Role of S100A3 in human colorectal cancer and the anticancer effect of cantharidinate.

Authors:  Bin Liu; Wen-Yi Sun; Chen-Yang Zhi; Tian-Cheng Lu; Hai-Mei Gao; Jian-Hua Zhou; Wei-Qun Yan; Hai-Cheng Gao
Journal:  Exp Ther Med       Date:  2013-10-14       Impact factor: 2.447

6.  The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study.

Authors:  Alison Clements; Eila Watson; Tanvi Rai; Colleen Bukach; Brian Shine; Joan Austoker
Journal:  BMC Fam Pract       Date:  2007-06-25       Impact factor: 2.497

Review 7.  The Clinical Efficacy of Prostate Cancer Screening in Worldwide and Iran: Narrative Review.

Authors:  Shima Shahyad; Seyed Hassan Saadat; Seyed-Mostafa Hosseini-Zijoud
Journal:  World J Oncol       Date:  2018-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.